Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Morgan Stanley (MS) Price & Performance

AstraZeneca plcTrade
Morgan StanleyTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Morgan Stanley — how do they compare? AstraZeneca plc trades at $159.37 (market cap $250.84B), while Morgan Stanley trades at $216.3 (market cap $338.50B). The key difference: Morgan Stanley is the larger of the two by market cap, and Morgan Stanley pays the higher dividend (2.14%). Which is the better fit depends on your goals.

AZNMS
Market Cap
$250.84B$338.50B
Sector
HealthFinancials
52-Week High
$209.48$228.42
52-Week Low
$147.06$144.04
Enterprise Value
$278.12B
Dividend Yield
1.97%2.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).

The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.

Morgan Stanley

Morgan Stanley (MS) trades at $215.1, down 0.54% on the day, with a neutral technical signal and key support at $214. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.46 surpassing expectations of $2.89. Revenue growth accelerated to $66.0B in 2025, and net income margin improved to 25.56%. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.

The outlook remains positive with a consensus price target of $239.58, implying 11% upside. Strengths include robust profitability and strategic initiatives, but risks involve volatile cash flows from operations and high leverage. Analyst sentiment is bullish with 56% buy ratings, though investors should monitor debt levels and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Morgan Stanley

Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.

Read more on MS